Image

North America SJS/TEN Treatment Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

North America SJS/TEN Treatment Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Published Report
  • May 2023
  • North America
  • 350 Pages
  • No of Tables: 186
  • No of Figures: 55

North America SJS/TEN Treatment Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 1,930.49 USD Million
Diagram Market Size (Forecast Year) USD 3,485.81 USD Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

North America SJS/TEN Treatment Market, By Treatment (Medications, Support care, Hospitalization, Isolation, Ointments and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures and Others), Cause (Specific Treatment, Infection and Others), Route of Administration (Oral, Parenteral, Topical and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting and Others), Distribution Channel (Retail Pharmacies, Direct Tender and Others) - Industry Trends and Forecast to 2030.

North America SJS/TEN Treatment Market

North America SJS/TEN Treatment Market Analysis and Insights

The treatment market for stevens-johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) is relatively small due to the rarity of these diseases.

North America SJS/TEN treatment market is dominated by drugs, as drugs are the main form of treatment for these conditions. Corticosteroids, intravenous immunoglobulin (IVIG), and antibiotics are the most commonly used medications in the treatment of SJS/TEN.

North America SJS/TEN Treatment MarketNorth America SJS/TEN Treatment Market

North America SJS/TEN treatment market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.8% in the forecast period of 2023 to 2030 and is expected to reach USD 3,485.81 million by 2030 from USD 1,930.49 million in 2022.

North America SJS/TEN treatment market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million

Segments Covered

Treatment (Medications, Support Care, Hospitalization, Isolation, Ointments, and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures, and Others), Cause (Specific Treatment, Infection, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult, and Paediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting, and Others), Distribution Channel (Retail Pharmacies, Direct Tender, and Others)

Countries Covered

U.S., Canada, and Mexico

Market Players Covered

3M (U.S.), Cardinal Health (U.S.), BD (U.S.), Smith + Nephew (U.K.), Novartis AG (Switzerland), Amneal Pharmaceuticals LLC. (U.S.), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Colgate-Palmolive Company (U.S.), Merck & Co., Inc. (U.S.), Mölnlycke Health Care AB. (Sweden), Xttrium Laboratories (U.S.), Schülke & Mayr GmbH (Germany), ICPA Health Products Ltd (India), Purdue Pharma L.P. (U.S.), eugia (Subsidiary of Aurobindo Pharma), and AdvaCare Pharma (U.S.) among others 

Market Definition

Stevens-johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening skin conditions that usually result from severe drug reactions. These conditions cause the top layer of skin to separate from the layers below, resulting in painful blisters and sores that can cover much of the body. SJS affects a smaller part of the skin, while TEN affects a larger part of the skin.

The definition of the SJS/TEN treatment market refers to products and services designed to manage and treat these conditions. There are drugs, therapies, and other treatments in the market that can help relieve SJS/TEN symptoms and improve patients' quality of life.  The drug market for the treatment of SJS/TEN includes a number of drugs that are used to relieve symptoms and treat the underlying cause.

North America SJS/TEN Treatment Market Dynamics

This section deals with understanding the market drivers, advantages, restraints, and challenges. All of this is discussed in detail below:

Drivers

  • Increasing Prevalence and Incidence of SJS/TEN

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious and potentially life-threatening conditions involving the skin and mucous membranes. SJS and TEN are considered two ends of the disease spectrum, with SJS being the milder form and TEN being the more severe form. A characteristic feature of these conditions is the separation of the epidermis (the outer layer of the skin) from the dermis (the layer below the skin) due to a strong immune reaction.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious skin diseases characterized by the separation of the epidermis from the dermis. The incidence of SJS/TEN has been reported to be around 1 per million people per year. However, in recent years there has been increased concern about the incidence and prevalence of SJS/TEN. 

  • Advances in Drug Development for SJS/TEN Treatment

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious and potentially life-threatening conditions that require prompt and aggressive treatment. Although there is currently no specific medication or treatment that can cure SJS/TEN, advances in drug development have led to better treatment strategies and treatment outcomes for affected patients. But there are various clinical trials going on for drug development for SJS/TEN treatment.

Restraint

  • High Cost Associated With the Treatment of SJS/TEN

One of the main reasons why SJS/TEN treatment is expensive is the need for intensive and long-term treatment. Patients with SJS/TEN often require hospitalization in specialized burn units, where they receive 24-hour care from a team of health professionals including dermatologists, ophthalmologists, and critical care specialists. Hospitalization can last several weeks and in severe cases even months. This can lead to high hospital bills and other related costs such as transportation, accommodation, and meals.

Opportunity

  • Developing Effective and Safe Treatment for SJS/TEN

Stem cell transplantation is a new approach that aims to replace damaged skin and mucous membranes with healthy tissue. Autologous stem cell transplantation, where stem cells are taken from the patient's skin and grown in culture before being transplanted back into the damaged area, has shown promising results in small studies.

Challenge

  • Stringent Government Regulations for Approval of a Treatment for SJS/TEN 

The strict government regulations for the approval of SJS/TEN treatments are related to the complex and rigorous process that pharmaceutical companies and their drugs must go through to obtain approval for an SJS/TEN treatment from regulatory agencies such as the US Food and Drug Administration. (FDA) or the European Medicines Agency (EMA).

The approval process for a new drug usually involves several stages of clinical trials in humans to assess the drug's safety and effectiveness.

Recent Developments

  • In June 2020, BD, a leading Asia-Pacific medical technology company announced that they have completed the acquisition of Straub Medical AG, a privately-held company. With this acquisition, the company has added the valuable expertise and experience of Straub Medical AG and expanded its product portfolio. This will help the company to expand and grow in the market.
  • In January 2019, Mölnlycke Health Care AB. acquires MandJ Airlaid Products A/S to further strengthen its wound care capabilities. In connection with the acquisition, MandJ, and its employees will be an integral part of Mölnlycke. The acquisition will improve Mölnlycke's security of supply for the air-laid material needed to produce advanced wound dressings and help grow the wound care business by accelerating innovation and product development in existing and future products. This will help the company to expand and grow in the market.

North America SJS/TEN Treatment Market Scope

North America SJS/TEN treatment market is categorized into nine notable segments based on treatment, diagnosis, cause, route of administration, drug type, therapy type, patient type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

North America SJS/TEN treatment market is categorized into nine notable segments based on treatment, diagnosis, cause, route of administration, drug type, therapy type, patient type, end user, and distribution channel.

Treatment

  • Medications
  • Support Care
  • Ointments
  • Hospitalization
  • Isolation
  • Others

On the basis of treatment, the North America SJS/TEN treatment market is segmented into medications, support care, hospitalization, isolation, ointments, and others.

Diagnosis

  • Physical Exam
  • Medical History
  • Skin Biopsy
  • Blood Test
  • Cultures
  • Others

On the basis of diagnosis, the North America SJS/TEN treatment market is segmented into physical exam, skin biopsy, medical history, blood test, cultures, and others.

Cause

  • Specific Treatment
  • Infection
  • Others

On the basis of cause, the North America SJS/TEN treatment market is segmented into specific treatment, infection, and others.

Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Others

On the basis of route of administration, the North America SJS/TEN treatment market is segmented into oral, parenteral, topical, and others.

Drug Type

  • Branded
  • Generic

On the basis of drug type, the North America SJS/TEN treatment market is segmented into branded and generic.

Therapy Type

  • Monotherapy
  • Combination Therapy

On the basis of therapy type, the North America SJS/TEN treatment market is segmented into combination therapy and monotherapy.

Patient Type

  • Pediatric
  • Adult
  • Geriatric

On the basis of patient type, the North America SJS/TEN treatment market is segmented into geriatric, adult and pediatric. 

End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Center
  • Homecare Setting
  • Others

On the basis of end user, the North America SJS/TEN treatment market is segmented into hospitals, specialty clinics, ambulatory surgical center, homecare setting, and others.

Distribution Channel

  • Direct Tenders
  • Retail Pharmacies
  • Others 

On the basis of distribution channel, the North America SJS/TEN treatment market is segmented into retail pharmacies, direct tenders, and others.

TEN Treatment Market Market

North America SJS/TEN Treatment Market Regional Analysis/Insights

North America SJS/TEN treatment market is categorized into nine notable segments which are treatment, diagnosis, cause, route of administration, drug type, therapy type, patient type, end user, and distribution channel.

The countries covered in this market report U.S., Canada, and Mexico.

U.S. is expected to dominate due to the presence of key market players in the largest consumer market with high GDP. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America SJS/TEN Treatment Market Share Analysis

North America SJS/TEN treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the North America SJS/TEN treatment market.

Some of the major players operating in the North America SJS/TEN treatment market are 3M (U.S.), Cardinal Health (U.S.), BD (U.S.), Smith + Nephew (U.K.), Novartis AG (Switzerland), Amneal Pharmaceuticals LLC. (U.S.), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Colgate-Palmolive Company (U.S.), Merck & Co., Inc. (U.S.), Mölnlycke Health Care AB. (Sweden), Xttrium Laboratories (U.S.), Schülke & Mayr GmbH (Germany), ICPA Health Products Ltd (India), Purdue Pharma L.P. (U.S.), eugia (Subsidiary of Aurobindo Pharma), and AdvaCare Pharma (U.S.) among others.


SKU-

TABLE 1 NORTH AMERICA SJS/TEN TREATMENT MARKET, PATENT ANALYSIS

TABLE 2 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 3 NORTH AMERICA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 NORTH AMERICA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 5 NORTH AMERICA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 6 NORTH AMERICA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 7 NORTH AMERICA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 8 NORTH AMERICA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 9 NORTH AMERICA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 10 NORTH AMERICA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 11 NORTH AMERICA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 12 NORTH AMERICA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 13 NORTH AMERICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 NORTH AMERICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 18 NORTH AMERICA HOSPITALIZATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA ISOLATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 NORTH AMERICA OINTMENTS IN JS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 24 NORTH AMERICA PHYSICAL EXAM IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA SKIN BIOPSY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA MEDICAL HISTORY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 NORTH AMERICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA CULTURES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA SPECIFIC TREATMENT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA INFECTION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 36 NORTH AMERICA ORAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 NORTH AMERICA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 38 NORTH AMERICA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 39 NORTH AMERICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 NORTH AMERICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 41 NORTH AMERICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 43 NORTH AMERICA BRANDED IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 NORTH AMERICA BRANDED IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 45 NORTH AMERICA GENERIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 47 NORTH AMERICA COMBINATION THERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 NORTH AMERICA MONOTHERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 49 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 50 NORTH AMERICA GERAITRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 NORTH AMERICA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 52 NORTH AMERICA ADULT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 53 NORTH AMERICA ADULT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 54 NORTH AMERICA PEDIATRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 56 NORTH AMERICA HOSPITALS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 NORTH AMERICA SPECIALTY CLINICS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 58 NORTH AMERICA AMBULATORY SURGICAL CENTER IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 NORTH AMERICA HOMECARE SETTING IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 60 NORTH AMERICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 61 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 62 NORTH AMERICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 63 NORTH AMERICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 64 NORTH AMERICA DIRECT TENDERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 65 NORTH AMERICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 66 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 67 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 68 NORTH AMERICA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 69 NORTH AMERICA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 70 NORTH AMERICA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 71 NORTH AMERICA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 72 NORTH AMERICA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 73 NORTH AMERICA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 74 NORTH AMERICA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 75 NORTH AMERICA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 76 NORTH AMERICA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 77 NORTH AMERICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 78 NORTH AMERICA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 79 NORTH AMERICA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 80 NORTH AMERICA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 81 NORTH AMERICA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 82 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 83 NORTH AMERICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 84 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 85 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 86 NORTH AMERICA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 87 NORTH AMERICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 88 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 89 NORTH AMERICA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 90 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 91 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 92 NORTH AMERICA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 93 NORTH AMERICA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 94 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 95 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 96 NORTH AMERICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 97 U.S. SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 98 U.S. MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 99 U.S. ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 100 U.S. CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 101 U.S. ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 102 U.S. ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 103 U.S. ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 104 U.S. CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 105 U.S. CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 106 U.S. OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 107 U.S. SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 108 U.S. PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 109 U.S. BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 110 U.S. BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 111 U.S. OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 112 U.S. SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 113 U.S. BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 114 U.S. SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 115 U.S. SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 116 U.S. PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 117 U.S. TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 118 U.S. SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 119 U.S. BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 120 U.S. SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 121 U.S. SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 122 U.S. GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 123 U.S. ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 124 U.S. SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 125 U.S. SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 126 U.S. RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 127 CANADA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 128 CANADA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 129 CANADA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 130 CANADA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 131 CANADA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 132 CANADA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 133 CANADA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 134 CANADA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 135 CANADA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 136 CANADA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 137 CANADA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 138 CANADA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 139 CANADA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 140 CANADA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 141 CANADA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 142 CANADA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 143 CANADA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 144 CANADA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 145 CANADA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 146 CANADA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 147 CANADA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 148 CANADA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 149 CANADA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 150 CANADA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 151 CANADA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 152 CANADA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 153 CANADA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 154 CANADA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 155 CANADA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 156 CANADA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 157 MEXICO SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 158 MEXICO MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 159 MEXICO ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 160 MEXICO CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 161 MEXICO ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 162 MEXICO ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 163 MEXICO ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 164 MEXICO CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 165 MEXICO CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 166 MEXICO OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 167 MEXICO SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 168 MEXICO PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 169 MEXICO BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 170 MEXICO BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 171 MEXICO OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 172 MEXICO SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 173 MEXICO BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 174 MEXICO SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 175 MEXICO SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 176 MEXICO PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 177 MEXICO TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 178 MEXICO SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 179 MEXICO BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 180 MEXICO SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 181 MEXICO SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 182 MEXICO GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 183 MEXICO ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 184 MEXICO SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 185 MEXICO SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 186 MEXICO RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The North America SJS/TEN Treatment Market is projected to grow at a CAGR of 7.8% during the forecast period by 2030.
The future market value of the North America SJS/TEN Treatment Market is expected to reach USD 3,485.81 million by 2030.
The major players in the North America SJS/TEN Treatment Market are 3M (U.S.), Cardinal Health (U.S.), BD (U.S.), Smith + Nephew (U.K.), Novartis AG (Switzerland), Amneal Pharmaceuticals LLC. (U.S.), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Colgate-Palmolive Company (U.S.), etc.
The countries covered in the North America SJS/TEN Treatment Market are U.S., Canada, and Mexico.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials